You are here

Alexion

AZ's Alexion inks $125M deal to resolve investor lawsuit over Soliris sales tactics

AZ's Alexion inks $125M deal to resolve investor lawsuit over Soliris sales tactics

Fierce Pharma

Flag link:

EHA 2023 – Astrazeneca keeps up its complement defense

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Flag link:

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

Fierce Biotech

Flag link:

AstraZeneca pays 666% premium to buy genomic medicine biotech

AstraZeneca pays 666% premium to buy genomic medicine biotech

Fierce Biotech

LogicBio Therapeutics

genomic medicine

Flag link:

AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3

AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3

Fierce Biotech

paroxysmal nocturnal hemoglobinuria

Flag link:

Data backs AZ’s Wilson disease drug, but with a question mark

Data backs AZ’s Wilson disease drug, but with a question mark

Pharmaforum

Flag link:

AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven

AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven

Fierce Biotech

Flag link:

AstraZeneca and Neurimmune close agreement to develop monoclonal antibody, NI006

AstraZeneca and Neurimmune close agreement to develop monoclonal antibody, NI006

Biopharma Reporter

monoclonal antibodies

transthyretin amyloid cardiomyopathy

Flag link:

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Endpoints

Flag link:

AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006

AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006

Biopharma Reporter

Flag link:

AstraZeneca blocks investor group's $7.6B buyout of rare disease specialist Sobi: report

AstraZeneca blocks investor group's $7.6B buyout of rare disease specialist Sobi: report

Fierce Pharma

Flag link:

AstraZeneca’s Alexion concludes Caelum acquisition for $500m

AstraZeneca’s Alexion concludes Caelum acquisition for $500m

Pharmaceutical Business Review

Caelum Biosciences

Flag link:

AstraZeneca lays out $360M for 'next-gen' manufacturing plant in Dublin

AstraZeneca lays out $360M for 'next-gen' manufacturing plant in Dublin

Fierce Pharma

drug manufacturing

Flag link:

After Ultomiris stumble, Alexion delivers a rare disease win for AZ

After Ultomiris stumble, Alexion delivers a rare disease win for AZ

Pharmaforum

Flag link:

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Fierce Pharma

myasthenia gravis

Flag link:

AstraZeneca heralds new chapter as Alexion acquisition completed

AstraZeneca heralds new chapter as Alexion acquisition completed

Biopharma Reporter

Flag link:

Biopharma throws grease on the deal wheels

Biopharma throws grease on the deal wheels

EP Vantage

Prevail Therapeutics

Flag link:

Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms

Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms

Fierce Pharma

Flag link:

Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?

Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?

Motley Fool

Moderna Therapeutics

Flag link:

Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms

Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms

Endpoints

clinical trials

myasthenia gravis

Flag link:

Pages